GMED vs BIO
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Sep 09, 2026
GMED
BIO
Investment Advisor Scores
BIO
AI Analyst Insights
Detailed Metrics Comparison
| Metric | GMED | BIO | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 14.6628 | 42.3729 | GMED |
| PEG Ratio | 1.7253 | 1.1905 | BIO |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 5.9% | -0.1% | GMED |
| Earnings Growth | -26.2% | 18.7% | BIO |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 40.4/100 | 42.0/100 | BIO |
| Profit Margin | 17.0% | 8.6% | GMED |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | HOLD | HOLD | Tie |
Relative Price Performance (Last 90 Days)
Current Technical Phase
GMED
NeutralMixed signals - no dominant trend phase, RSI 32
BIO
MarkupPrice above SMA50, rising 50-day trend (11.2% over 20 days), RSI 51
Fundamentals Snapshot
| Metric | GMED | BIO |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | 13.7 | 36.8 |
| Trailing P/E | 19.1 | 45.9 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.1% | 0.0% |
| Gross Margin | 0.7% | 0.5% |
| Operating Margin | 0.2% | 0.1% |
| EPS | 3.86 | 8.04 |
| Dividend Yield | — | — |